Claritas Rx

Overview

Claritas Rx is a SaaS patient-journey analytics platform purpose-built for specialty and rare-disease brands. It aggregates feeds from specialty pharmacies, hub services, copay and free-drug programs, call centers, field access teams, and payer sources, then turns that fragmented signal into pre-dispense visibility, risk scoring, and case-coordination workflows. The buyer is the market access or patient services team at a manufacturer launching or managing a specialty therapy.

Claritas Rx is not a hub services operator, a specialty pharmacy, or a claims-based RWE vendor; it is the analytics and workflow layer that sits on top of those operating partners. Pre-dispense data coverage is the structural differentiator against claims-only competitors that only see prescriptions after dispense.

Platform Capability Model

The framework below standardizes how Rx Almanac evaluates data-technology-platforms capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Claritas Rx is evaluated as SaaS patient-journey analytics platform purpose-built for specialty and rare-disease brands.

Capability	Buyer should compare	Claritas Rx readout
Data aggregation and interoperability	Claims, EHR, CRM, pharmacy, provider, payer, and FHIR/API connectivity with normalization and identity resolution.	Major data foundation. Ingests and normalizes feeds from specialty pharmacies, hubs, copay/free-drug programs, call centers, field access, and payer sources into a single specialty patient view.
Commercial analytics and patient finding	Targeting, segmentation, patient finding, provider analytics, referral leakage, and opportunity sizing.	Major analytics use case. Patient-journey analytics, predictive abandonment risk scoring, and Access Analytics benchmarking are the platform’s primary differentiation.
Workflow automation and CRM integration	Case workflows, field workflows, CRM, task automation, document handling, and operational queue management.	Core workflow layer. Patient Watchtower CRM and the 2026 Omnichannel CRM extend Claritas from analytics into case-coordination workflow across hubs, SPs, and field teams.
Provider, payer, and pharmacy network connectivity	Network reach across HCPs, payers, pharmacies, labs, health systems, and transaction endpoints.	Major network reach. Direct SP / hub / copay partner integration is the operating model; pharmacy network reach is mediated through partners, not direct dispensing.
AI, NLP, and unstructured data extraction	Conversation intelligence, document AI, NLP extraction, predictive models, and model monitoring.	Automation workflow. AI-assisted risk scoring is positioned around first-fill and persistence; validate model performance evidence, validation methodology, and therapy-area applicability.
Security, compliance, and governance	HIPAA, SOC2, data-use controls, auditability, consent, privacy, and regulated-workflow safeguards.	Documented strength. Consent Clearinghouse consolidates patient permissions across partners in a single HIPAA-compliant environment, which matters when SP and hub partners share data with the manufacturer.
Reporting, dashboards, and data delivery	Dashboards, exports, APIs, scheduled reporting, and downstream feeds to analytics or operating teams.	Confirm reporting layer in the RFP. Confirm refresh cadence, export rights, dashboard access, API availability, and handoff into existing access or analytics environments.

Buyer Fit

• Buyer trigger: Use Claritas Rx when a specialty or rare-disease brand needs unified visibility across SP, hub, and copay partners with pre-dispense risk insight rather than claims-only reporting.
• Best-fit buyers: Market access, patient services, and brand analytics teams at specialty or rare-disease manufacturers launching or scaling a therapy with an SP / hub network.
• Less ideal fit: Retail brands without an SP-driven channel, teams seeking a hub services operator, or teams that only need national claims-based analytics.
• Commercial fit: Subscription pricing; assume an RFP-led scope with data feeds, SP / hub partner counts, consent governance, and dashboard access defined in the SOW.
• Staffing diligence: Confirm SP and hub partner integration coverage, consent and data-rights model, model performance evidence by therapy area, and how Claritas data flows into existing CRM, hub, and analytics environments.

Differentiators

• Pre-dispense visibility: Aggregating SP, hub, and copay data before dispense gives brand teams a structurally different view than claims-only competitors that only see fills after the fact.
• Patient Watchtower CRM: Case-coordination workflow tied directly to the patient-journey data layer, rather than a separate CRM bolted on after the analytics.
• Consent Clearinghouse: Centralized patient permissions across partners reduce consent fragmentation that often blocks pharma teams from acting on SP / hub data.
• Access Analytics benchmarking: Real-time access performance benchmarking against the specialty market is hard to replicate without comparable cross-brand SP / hub data.
• Specialty / rare-disease focus: The product, data model, and references are tuned for specialty therapies, not a general commercial analytics platform repurposed for specialty.

RFP Questions

• Which SP, hub, and copay partners are already integrated in production, and what is the onboarding timeline for partners not yet in the network?
• How is consent governed end-to-end through the Consent Clearinghouse, and what artifacts are available for legal and privacy review?
• What evidence supports the predictive risk-scoring models in this therapy area, including validation methodology, sample size, and abandonment baselines?
• How does Patient Watchtower CRM and the Omnichannel CRM integrate with existing hub, SP, and field-team workflows without duplicating queues?
• What dashboards, exports, APIs, and scheduled feeds are included, and how does data flow into manufacturer analytics, data lake, or CRM environments?
• Which references can demonstrate first-fill, persistence, or time-to-therapy improvement in similar specialty or rare-disease launches?
• How are refresh cadence, audit logs, data residency, and downstream data-use rights governed in the contract?

Recent Activity

• 2026-04: Patient Services Omnichannel CRM launched as a standalone product that unifies hub, SP, and field-team workflows into a single secure workspace; client references cite a 98% 24-hour response rate from hub and pharmacy partners.
• 2026-02: Integrated Data and Consent Clearinghouse solution announced, positioned around higher first-fill rates and long-term persistence across specialty and rare-disease brands.
• 2025: HealthVerity strategic partnership announced to extend Claritas data into commercial RWE and HEOR use cases.
• 2025: Named to Inc.’s 2025 Best Workplaces list and recognized by PM360 for the Patient Watchtower platform.